Status:
UNKNOWN
Anti-Mullerian Hormone (AMH) and Antral Follicle Count as Markers of Ovarian Reserve- Prospective Followup of Young Cancer Patients
Lead Sponsor:
Hadassah Medical Organization
Conditions:
Infertility
Eligibility:
FEMALE
5-45 years
Brief Summary
young female cancer patients have improving chances of survival. the main risk is a chronic damage to their ovarian reserve. This may lead to future infertility.
Detailed Description
our objective is to prospectively follow patients before and after their cancer treatment. this should help us learn of the gonadotoxicity of various treatments as well as be able to better consult th...
Eligibility Criteria
Inclusion
- all females prior and after chemotherapy
Exclusion
- do not consent
Key Trial Info
Start Date :
June 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2013
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00930501
Start Date
June 1 2009
End Date
December 1 2013
Last Update
June 30 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hadassah
Jerusalem, Israel